Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics Inc (NQ: AKRO )

32.10 -0.07 (-0.22%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 228,782
Open 32.35
Bid (Size) 30.37 (1)
Ask (Size) 32.90 (1)
Prev. Close 32.17
Today's Range 32.00 - 32.74
52wk Range 15.32 - 37.00
Shares Outstanding 50,086,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
From Akero Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+36.71%
+36.71%
1 Month
+4.12%
+4.12%
3 Month
+23.51%
+23.51%
6 Month
+67.27%
+67.27%
1 Year
+81.77%
+81.77%

More News

Read More
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
From Kahn Swick & Foti, LLC
Via Business Wire
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
From Kahn Swick & Foti, LLC
Via Business Wire
AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Via Benzinga
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)
From The Law Offices of Frank R. Cruz
Via Business Wire
AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
AKERO THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
From Kahn Swick & Foti, LLC
Via Business Wire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
From The Rosen Law Firm PA
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.